Everolimus Offers No Survival Benefit in Non–Clear Cell RCC ...Middle East

Medscape - News
A secondary analysis of the EVEREST trial found that adjuvant everolimus did not provide a recurrence-free or overall survival benefit in patients with localized non–clear cell RCC. Medscape Medical News

Hence then, the article about everolimus offers no survival benefit in non clear cell rcc was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Everolimus Offers No Survival Benefit in Non–Clear Cell RCC )

Apple Storegoogle play

Last updated :

Also on site :